Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

By S. Johnston, J. Pippen, X. Pivot, M. Lichinitser, S. Sadeghi, V. Diéras, H. Gómez, G. Romieu, A. Manikhas, M. Kennedy and 7 more. Journal of Clinical Oncology, 2009

1,033 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/5a9e3a57b0fbcf2e67c2211c12bcaf0fa3a24b89

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Aleix Prat
2. Charles M. Perou

Citations in the corpus

• Targeting the EGFR signaling pathway in cancer therapy (2012, background): “A double-blinded, multi-center study consisting of 1286 patients with advanced breast cancer, of which 219 had HER2-positive tumors, revealed that the combination of lapatinib and letrozole had improved the progressionfree survival when compared to monotherapy with letrozole alone [97-99].”
• Deconstructing the molecular portraits of breast cancer (2010, background): “Two clinical trials have tested this hypothesis and have demonstrated that a combined endocrine and anti-HER2 approach significantly enhances progression-free survival and clinical benefit rates in patients with HRþ/HER2þ metastatic breast cancer (Johnston et al., 2009; Kaufman et al., 2006).”